Daily coverage of equity markets, sectors, and major indices.
In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.
29,610 total articles
Apple reported FQ3 2026 results that topped consensus on both EPS and revenue, but shares fell about 7.6% pre-market to roughly $308 as Q4 revenue guidance of 9-11% missed the roughly 12% consensus. The company's beat included a $0.11 EPS boost from tariff refunds, and investors zeroed in on weaker Services revenue, a slowdown in Greater China, and…
Acciona's shares fell about 3% after the company reported an 84.3% year-on-year decline in attributable net profit for the first half of 2026, driven by the lack of asset rotation gains that lifted H1 2025 and a swing to a loss at its renewable subsidiary. Management points to July asset disposals and a stronger second half, but investors and analy…
Colgate-Palmolive reaffirmed its full-year net sales guidance after reporting a quarterly sales increase, even as organic sales in North America declined. The company cited volume weakness, market share pressure and inventory reductions at major retailers, while warning that new U.S. tariffs will more than offset recent tariff refunds. Adjusted pro…
Vitol Group and Cargill Inc. have stopped trading with Radiant World, while Glencore Plc has suspended new business with the private iron ore trader amid concerns that some trade documents provided by Radiant World to lenders were invalid. Several banks and credit funds are reviewing exposure to the company, which has expanded rapidly in the iron o…
New York's attorney general has sued KalshiEX, LLC in Manhattan state court, accusing the prediction-market operator of running an unlicensed gambling business. The complaint seeks to halt Kalshi's operations in the state, require forfeiture of alleged illegal gains, impose fines and provide restitution to harmed consumers. The suit asserts Kalshi'…
Monte Rosa Therapeutics shares plunged in pre-market trading after Novo Nordisk reported that its Phase 3 ZEUS cardiovascular outcomes study of ziltivekimab did not produce a statistically meaningful reduction in major adverse cardiovascular events. The result, which produced a hazard ratio essentially equal to 1.0, undercut confidence that targeti…
Barclays points to L'Oreal as a primary beneficiary of current trends in the European beauty market after Puig reported resilient, selective growth in the first half. While fragrance, makeup and dermocosmetics are expanding, premium skincare has softened as consumers shift toward efficacy and value. Puig's H1 metrics—including 4.4% like-for-like gr…
Moody's Investors Service lowered the ratings on three Carnival Corporation Ltd. and Carnival UK Ltd. senior note issues to Ba1 from Baa2 after the notes lost secured status when collateral was released. The downgrade affects roughly $3.1 billion of notes, while Moody's kept Carnival's Ba1 corporate family rating and Ba1 senior unsecured rating int…
A recent survey of market participants indicates the Bank of England is likely to reduce the annual pace at which it is shrinking its government bond holdings to £50 billion in the 12 months ending September 2027, compared with a £70 billion pace in the current 12-month period. The survey, released Friday, mirrors the central bank's previous Market…
BioAge Labs shares plunged more than half in pre-market trading after Novo Nordisk announced that ziltivekimab did not reduce major adverse cardiovascular events versus placebo in the Phase 3 ZEUS study. The result, seen despite evidence the drug suppressed the IL-6 pathway, has direct implications for BioAge's lead program BGE-102, an NLRP3 inhibi…
Morgan Stanley trimmed its full-year China GDP forecast by 20 basis points to 4.6% after June activity expanded 4.3%, missing both consensus and Beijing's target. The bank pointed to decelerating infrastructure spending after front-loading, weaker refining and petrochemical output tied to oil prices, and subdued consumption driven by fading trade-i…
Bank of America analysts argue that forward-looking inflation metrics have become the primary barometer of Federal Reserve credibility following recent comments from Fed leadership that markets are effectively tightening policy. BofA singles out the 5-year, 5-year forward breakeven inflation rate as the Fed's preferred market-based read, notes rece…
Futures linked to Canada’s main equity gauge inched higher on Friday as investors absorbed a heavy calendar of corporate results and positioned for upcoming domestic GDP figures. Strength in metal mining names, a rebound in U.S. technology and ongoing commodity swings underpinned the moves, while traders continued to weigh the Federal Reserve’s pol…
Goldman Sachs says European companies are topping earnings forecasts in the current reporting season, with roughly two-thirds of the STOXX Europe 600 having reported. Aggregate earnings-per-share surprises are running near 3%, and first-half EPS is tracking about 13% year-over-year - the fastest pace in three years. Sector revisions have mostly tre…
Boston Scientific shares were down 0.4% in pre-market trade as the company extends losses following its Q2 2026 results released two days earlier. While revenue and adjusted EPS beat consensus, management trimmed full-year adjusted EPS and net sales growth guidance for the second straight quarter, citing an unexpected drop in U.S. WATCHMAN stand-al…
AbbVie shares fell sharply in pre-market trading after the company released second-quarter 2026 results and reiterated guidance that came in below Wall Street expectations. A previously disclosed $291 million IPR&D and milestones charge that trims EPS by $0.17 per share, combined with adjusted Q2 EPS guidance beneath consensus, prompted a class…
AbbVie narrowed its 2026 adjusted earnings forecast to reflect the planned $10.9 billion acquisition of Apogee Therapeutics, while reporting second-quarter results that exceeded analyst estimates thanks to robust sales of immunology medicines. The company expects the Apogee transaction to lower 2026 earnings by $0.14 per share and still delivered q…
Barclays strategists say that as bond market volatility increases and long-duration supply expands, corporate earnings will need to do more to underpin equity prices. The firm points to higher oil, uncertainty over the Federal Reserve's reaction function after Fed Chair Warsh's comments, and heavy capex from hyperscalers as drivers of recent market…
Eaton Corporation PLC rallied in pre-market trade after reporting second-quarter 2026 results that outpaced analyst forecasts on both earnings and revenue, and after issuing third-quarter adjusted EPS guidance above consensus. Management’s continued pattern of conservative targets, ongoing portfolio changes, and broad market strength combined to pu…
Clariant AG shares climbed after the company reported second-quarter results that exceeded analyst forecasts, coupled with a court ruling that dismissed a sizeable damages claim. The combination of stronger-than-expected adjusted EBITDA and sales, higher cost-savings targets and above-target free cash flow underpinned investor confidence and lifted…
Novo Nordisk shares dropped sharply in pre-market trading after its IL-6 inhibitor ziltivekimab failed to lower major adverse cardiovascular events in the Phase 3 ZEUS trial. The hazard ratio versus placebo was 0.99 across more than 6,300 patients. The result removes an anticipated pipeline catalyst and follows a court decision allowing a sharehold…
U.S. equity futures rose as investor optimism around artificial intelligence spending strengthened demand for technology and semiconductor stocks following a robust cloud update from Amazon. Major movers included Amazon, which jumped after reporting its strongest cloud revenue growth in over four years and disclosing a $25 billion annual run rate f…
Rocket Lab shares advanced in pre-market trading after the company signed a third consecutive multi-launch agreement with Japanese synthetic aperture radar operator iQPS for three more dedicated Electron launches. The deal raises iQPS's total Electron missions to 18 and comes as analysts maintain bullish ratings and investors position ahead of Rock…
U.S. equity mutual funds and ETFs recorded net inflows in the week through July 29, driven by renewed interest in mega-cap technology names following robust earnings from Microsoft and Amazon. The $11.83 billion of net purchases into U.S. equities more than offset the $10.68 billion pulled over the prior two weeks, while flows into bond funds slowe…
Novo Nordisk shares plunged after the company disclosed that its experimental IL-6 inhibitor ziltivekimab did not reduce major adverse cardiovascular events (MACE) in the Phase 3 ZEUS trial. While the drug hit biological targets by lowering free IL-6 and high-sensitivity C-reactive protein, the study produced a hazard ratio of 0.99 (95% CI: 0.88 to…
